COGNIGY
17.12.2020 06:03:08 CET | Business Wire | Press release
Cognigy , a global leader in Conversational AI, and Telekom , a leading telecommunications provider, today announced a new partnership aimed at improving the customer journey through greater automation in customer service. With its Conversational AI Suite, Telekom offers artificial intelligence (AI) solutions individually tailored to customer concerns in collaboration with leading technology partners.
“Our AI solutions support the customer journey in customer service from start to finish by handling frequently occurring customer concerns in an automated and successful way. This reduces the customer service staff’s workload and cuts costs,” Waldemar Mach, Product Manager UC & AI Managed Solutions, Telekom Germany GmbH, explains. “Cognigy.AI is a perfect fit for our solution portfolio, both functionally and technically, as it is highly integrative, extremely flexible in its use with both voice and chat services and designed to handle large volumes of dialog.”
“We are pleased to have found another strong partner who is enthusiastic about Cognigy.AI. The partnership with Telekom underscores Cognigy’s proficiency in the area of smart automation of customer communications,” said Marc Schneider, VP of Partnerships EMEA at Cognigy. “Telekom’s expertise in the areas of service, operations, and project management, paired with our easy-to-use low-code platform, guarantees trouble-free, GDPR (General Data Protection Regulation)-compliant projects and fast ROIs.”
First Conversational AI Project for the Telekom Baskets
In a first joint Cognigy.AI project, Telekom improved the digital experience of the basketball team it sponsors, the Telekom Baskets. The aim was to employ a digital assistant and make fan interaction more efficient, more emotional, and unlimited in terms of time. A particular highlight of the solution is the digitization of the Baskets’ mascot. “Bonni” was measured and filmed in various poses to create a likable 3D avatar with high recognition value for the fans.
Fans can chat with the virtual mascot and get information from it at www.telekom-baskets-bonn.de anytime. Bonni provides support with any queries relating to tickets, the fan store, the match schedule, the team, or directions to the Telekom Dome. The avatar also reacts to events in real time, for example jumping in the air when a positive message is received, clapping its hands, or cheering, which lends an emotional touch to the interaction. The team behind Bonni can adapt and expand chat dialogs constantly, thanks to the intuitive usability of Cognigy.AI.
In addition to Telekom, Cognigy offers its customers a broad network of skilled local and global implementation and IT system partners with relevant industry and subject specializations. Find a qualified partner on the Cognigy partner network page: www.cognigy.com/partner
Cognigy offers all business users the opportunity to experience Conversational AI for themselves. Try a personalized demo for your own use case or try a free test environment .
About Cognigy
Cognigy is a global leader in Conversational AI to support customer service automation. Its low-code platform, Cognigy.AI, enables enterprises to automate contact centers for customer and employee communications using intelligent voice- and chatbots. With precise, reliable intent recognition, human-like dialogs and seamless integration into backend systems, Cognigy.AI creates superior user experiences and helps companies reduce support costs. Cognigy.AI is available in SaaS and on-premise environments and supports conversations in any language and on any channel including phone, webchat, SMS and mobile apps. Cognigy’s worldwide client portfolio includes Daimler, Bosch, Henkel, Lufthansa, Salzburg AG and many more. Learn more at cognigy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216006018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
Boomi Teams up With Gong to Bring Revenue AI to Boomi Agentstudio14.5.2026 18:00:00 CEST | Press release
Gong's revenue AI is now natively available in the Boomi Enterprise Platform Boomi, the data activation company for AI, today announced a collaboration withGong, the leader in Revenue AI, to bring revenue signals captured in Gong natively into the Boomi Enterprise Platform. This collaboration enables enterprises to establish an active data foundation designed to transform customer conversations into coordinated, automated actions across systems and functions enterprise-wide with Boomi Agentstudio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514443012/en/ Boomi Teams Up with Gong to Bring Revenue AI to Boomi Agentstudio Gong goes beyond capturing deal activity to surface real-time insights into risk, buyer intent, competitive dynamics, and key engagement signals. That intelligence moves from conversation to coordinated action, flowing across CRM, ERP, product, and operational systems with the governance and security tha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom